Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo

24 Nov 2014

Abstract excerpt

// Xiao-kun Wang 1 , Kenneth Kin Wah To 2 , Li-yan Huang 1 , Jing-hong Xu 3 , Ke Yang 1 , Fang Wang 1 , Zhen-cong Huang 1 , Sheng Ye 3 , Li-wu Fu 1 1 State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China 2 School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, P.R. China 3 First Affiliated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Drug Transport and Resistance Mechanisms
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25436978
DOI: 10.18632/oncotarget.2647

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivoPMID 25436978Read ↗

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studiesSemantic proximity Read ↗

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.Semantic proximity Read ↗

Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signallingSemantic proximity Read ↗

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterationsSemantic proximity Read ↗

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug ResistanceSemantic proximity Read ↗

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor CellsSemantic proximity Read ↗

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter ProteinsSemantic proximity Read ↗

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistanceSemantic proximity Read ↗

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer CellsSemantic proximity Read ↗

Afatinib: first global approval.Semantic proximity Read ↗

A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.